Ma Songjiang's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed Feb 25, 2025
- Accession no.
- 0001140361-25-005842
- Filed
- Feb 25, 2025
- Trade date
- Feb 21-24, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions. Open-market sales total $45.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ma SongjiangCIK 0001985547 | Director, Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 21, 2025 | Common Stock | SSaleDisposed | −1,818 | $11.84F2 | −$21,525.12 | 2,861,442 | Indirect | |
| Feb 21, 2025 | Common Stock | SSaleDisposed | −182 | $12.60F3 | −$2,293.2 | 2,861,260 | Indirect | |
| Feb 24, 2025 | Common Stock | SSaleDisposed | −1,813 | $10.60F4 | −$19,217.8 | 2,859,447 | Indirect | |
| Feb 24, 2025 | Common Stock | SSaleDisposed | −187 | $11.52F5 | −$2,154.24 | 2,859,260 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.54 to $12.53. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.71. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.41 to $11.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.43 to $11.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.